Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: effects of variation in stimulation parameters

M Rizzone, M Lanotte, B Bergamasco, A Tavella, E Torre, G Faccani, A Melcarne, L Lopiano

Abstract
Objective—To investigate the relation between the variation of the parameters of stimulation and the clinical effectiveness in parkinsonian patients treated with deep brain stimulation of the subthalamic nucleus (STN), to provide information on the electrical parameter setting and the mechanism of action of deep brain stimulation.

Methods—Ten patients with Parkinson’s disease bilaterally implanted in the STN were studied. For every patient the intensity of the stimulus necessary to obtain the disappearance of contralateral wrist rigidity (required clinical effect, RCE) and the side effect threshold in 20 different conditions of stimulation, coupling four pulse width values (60, 120, 210, 450 µs) with five rate values (10, 50, 90, 130, 170 Hz) were determined. All the patients were tested after a 12 hour withdrawal of antiparkinsonian drugs, and the clinical evaluation was double blind.

Results—In all the patients it was impossible to obtain the RCE using 10 and 50 Hz stimulus rates. For all the other stimulus rate values, the intensity-pulse width curves (IPWCs) for the RCE and for the side effect threshold showed a hyperbolic trend. For every pulse width value, increasing the rate from 90 to 130 and to 170 Hz progressively decreased the intensity of the stimulus necessary to reach the RCE, but the differences were not significant. Within the same rate value, the progressive reduction of the stimulus intensity necessary to obtain the RCE, obtained with the lengthening of the pulse width was significant (p<0.05) only comparing 60 with 210 µs and 60 with 450 µs.

Conclusions—The findings give some useful indications for the electrical parameter setting in deep brain stimulation of the STN, and some information about the mechanism of action of deep brain stimulation.

Keywords: Parkinson’s disease; subthalamic nucleus; deep brain stimulation

Deep brain stimulation of the subthalamic nucleus (STN) has been shown to be an effective therapeutic option for advanced Parkinson’s disease.1–4 The hyperactivity of STN neurons plays an important part in the pathophysiology of Parkinson’s disease symptoms.5–7 Through chronic high frequency electrical stimulation it is possible to achieve a functional inhibition of the STN neurons, miming the effect of a lesion,8,9 with a consequent relevant improvement of the cardinal symptoms of the illness (tremor, rigidity, and akinesia).1–5 Moreover, this allows a significant reduction of dopaminergic drugs, with an improvement in drug induced dyskinesias.1–5

The mechanism of action of deep brain stimulation is still unknown10–12; the characteristics of the electrical stimulus, particularly the rate, ranging between 100 and 200 Hz,13 make a depolarising chronic effect unlikely.14,15 The synchronous and massive stimulation of an extensive neuronal pool could result in a disrupted output, leading to a functional block of the system; alternatively, the reduction of the firing rate of the hyperactive STN neurons could be explained by a preferential activation of the inhibitory GABAergic fibres projecting to the nucleus.16–17

One of the advantages of the deep brain stimulation technique is the possibility of varying the parameters of the stimulation (rate, pulse width, voltage) to obtain the best clinical improvement, avoiding side effects.18 At present, because of the lack of knowledge about the exact mechanism of action, few indications are available about the role of the different parameters of stimulation on the effectiveness of deep brain stimulation of the STN;10,11,14, therefore, the electrical parameter setting for implanted patients is still not standardised.

The main objective of this study was to investigate the relation between the variation of the parameters of stimulation (rate, pulse width, voltage) and the clinical effectiveness of deep brain stimulation of the STN in patients with Parkinson’s disease, to identify the pattern of stimulation capable of determining the best therapeutic window (the higher difference between the threshold for the clinical effectiveness and for the onset of side effects). For this purpose it was necessary to evaluate a constant clinical effect suitable for analysing the relation between the parameters of STN stimulation. In addition, this study may provide information about the mechanism of action of deep brain stimulation.

Patients and methods

Patients
Ten patients with advanced Parkinson’s disease were examined after the bilateral implantation of a
Table 1 Mean (SD) clinical characteristics of the patients

<table>
<thead>
<tr>
<th>Sex</th>
<th>6 men; 4 women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>62.3 (6.4)</td>
</tr>
<tr>
<td>Duration of disease (y)</td>
<td>15.9 (4.7)</td>
</tr>
<tr>
<td>Duration of levodopa treatment (y)</td>
<td>14.6 (5.1)</td>
</tr>
<tr>
<td>Duration of motor fluctuations (y)</td>
<td>6.5 (3.6)</td>
</tr>
<tr>
<td>Duration of dyskinesias (y)</td>
<td>6.0 (3.5)</td>
</tr>
<tr>
<td>Hoehn and Yahr stage-on</td>
<td>2.5 (0.4)</td>
</tr>
<tr>
<td>Hoehn and Yahr stage-off</td>
<td>4.0 (0.3)</td>
</tr>
<tr>
<td>Total UPDRS score-on</td>
<td>37.6 (11.6)</td>
</tr>
<tr>
<td>Total UPDRS score-off</td>
<td>94.6 (14.4)</td>
</tr>
<tr>
<td>UPDRS part II-on</td>
<td>7.4 (4.1)</td>
</tr>
<tr>
<td>UPDRS part II-off</td>
<td>26.7 (3.7)</td>
</tr>
<tr>
<td>UPDRS part III-on</td>
<td>19.1 (8.0)</td>
</tr>
<tr>
<td>UPDRS part III-off</td>
<td>56.4 (11.6)</td>
</tr>
<tr>
<td>Levodopa preoperative daily dosage (mg)</td>
<td>956.2 (541.0)</td>
</tr>
</tbody>
</table>

The implant was placed using a system of fusion of the CT and MRI images (Stereoplan, Radionics, USA) to detect the position of the STN in relation to the mid-commisural point; in addition, intraoperative neuronal electrical activity recording and macrostimulation were performed. Patients had been operated on at least 3 months before the study to avoid the interference of a surgical microlesive effect in the evaluation of deep brain stimulation.

Characteristics of the patients are shown in table 1. The mean age of the patients, four women and six men, was 62.3 years (range 51–70 years); the duration of the disease was 15.9 years, with an average duration of levodopa therapy of 14.6 years.

The average daily dosage of levodopa in the presurgical period was 956.2 mg/day. The average Hoehn and Yahr stage was 2.5 in the off phase and 4.0 in the on phase. In the preoperative period patients were evaluated with the unified Parkinson’s disease rating scale (UPDRS): the average score in the UPDRS part III (motor evaluation) was 19.1 in the on condition and 56.4 in the off condition. All patients gave their informed consent to the study.

Experimental Protocol

To assess the clinical effectiveness of the stimulation we tested subjectively the wrist rigidity contralateral to the stimulated side. We considered the disappearance of wrist rigidity with the patient resting as the clinical constant effect to obtain (required clinical effect, RCE).

Each patient was examined at one side only, generally the most compromised one, because of the time necessary for the execution of the study. For the test, we used the contact of the quadripolar electrode in the STN (DBS-3389, Medtronic, Minneapolis, MN, USA). The pulse generator was activated contralaterally to the examined side, on the most effective contact. To assess the effect of variation of the stimulation parameters we tested the patients in 20 different conditions, coupling four different pulse width values (60, 120, 210, 450 µs) with five rate values (10, 50, 90, 130, 170 Hz).

For each condition, the rate was increased until the RCE was reached; the corresponding value of current intensity was calculated and plotted on a diagram, drawing an intensity-pulse width curve (IPWC) for every rate value. When the RCE was reached, the patient’s rest tremor and akinesia were scored. Afterwards, the voltage was further increased until the onset of persistent side effects, and the corresponding value of current intensity was calculated.

The pulse generator was deactivated before every change of condition, until the reappearance of the contralateral baseline wrist rigidity. During the examination the order of the 20 different conditions of stimulation was random, and all the tests were performed with either the patient or the examiner unaware of the conditions of stimulation.

Statistical analysis was by Friedman’s test and the Student-Newman–Keuls test for multiple comparison; statistical significance was indicated by a p value <0.05.

Results

Clinical Efficacy

In the baseline condition the wrist rigidity mean score on the examined side was 2.6/4 (SD 0.6) (UPDRS III item 22).

Table 2 shows the mean values of intensity of the stimulus giving the RCE in the 20 different conditions of stimulation rate and pulse width.

With a stimulus rate of 10 and 50 Hz it was impossible to obtain the RCE with any pulse width apart from one patient that reached the RCE, with a rate of 50 Hz.

With a stimulus rate of 90, 130, or 170 Hz it was nearly always possible to obtain the RCE whatever pulse width was set; in two patients the onset of side effects made it impossible to reach the RCE with a stimulus rate of 90 Hz and a pulse width of 210 and 450 µs.
The trend of the IPWCs, looking at the constancy of the clinical effect, is shown in figure 1a. For every stimulus rate (90, 130, 170 Hz) and pulse width (60, 120, 210, 450 µs) the intensity of the stimulus necessary to obtain the RCE was identified, getting an IPWC similar for each stimulus rate, with a hyperbolic trend. For every pulse width value the increase of the stimulus rate from 90 Hz to 170 Hz led to a better clinical effect—namely a reduction of the intensity of the stimulus necessary to obtain the RCE. None of these differences were, however, significant.

Within the same stimulus rate value, the larger the pulse width the greater the effectiveness of the stimulation. These pulse width related differences on clinical efficacy were significant comparing 60 with 210 µs and 60 with 450 µs for every stimulation rate value.

Only four patients showed rest tremor in the baseline condition on the examined side, with an average score of 2.0/4 (SD 0.7) (UPDRS III item 20). In all the experimental conditions in which it was possible to obtain the RCE on wrist rigidity we also found an improvement of the rest tremor with respect to the baseline, whereas no substantial differences were found between the different conditions (table 3). Average baseline akinesia score for the examined upper limb was 6.6/12 (SD 2.9) (UPDRS III items 23, 24, 25). Also this symptom significantly improved when the RCE for wrist rigidity was reached, and no significant differences were found between the different experimental conditions (table 4).

**SIDE EFFECTS**

Table 5 shows the mean values of the stimulus intensity corresponding to the side effect threshold in the different experimental conditions.

![Figure 1](image-url)

**Table 2** Mean (SD) values of intensity (mA) corresponding to the reach of the required clinical effect (RCE)

<table>
<thead>
<tr>
<th>Pulse width (µs)</th>
<th>Rate (Hz)</th>
<th>90</th>
<th>130</th>
<th>170</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>1.7 (0.6)</td>
<td>1.4 (0.3)</td>
<td>1.3 (0.4)</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>1.3 (0.6)</td>
<td>1.1 (0.3)</td>
<td>1.0 (0.3)</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>1.1 (0.4)</td>
<td>1.0 (0.3)</td>
<td>0.8 (0.3)</td>
<td></td>
</tr>
<tr>
<td>450</td>
<td>0.9 (0.4)</td>
<td>0.8 (0.3)</td>
<td>0.7 (0.3)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3** Mean (SD) for tremor of the examined upper limb (UPDRS III, item 20) in the different experimental conditions. The scores are relative to the current intensity that determined the reaching of the RCE on wrist rigidity.

<table>
<thead>
<tr>
<th>Pulse width (µs)</th>
<th>Rate (Hz)</th>
<th>90</th>
<th>130</th>
<th>170</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>0.4 (0.5)</td>
<td>0.4 (0.5)</td>
<td>0.3 (0.3)</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>0.4 (0.5)</td>
<td>0.3 (0.3)</td>
<td>0.3 (0.3)</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>0.3 (0.3)</td>
<td>0.4 (0.5)</td>
<td>0.3 (0.3)</td>
<td></td>
</tr>
<tr>
<td>450</td>
<td>0.4 (0.3)</td>
<td>0.3 (0.3)</td>
<td>0.4 (0.5)</td>
<td></td>
</tr>
</tbody>
</table>

RCE=Required clinical effect.

**Table 4** Mean (SD) scores for akinesia of the examined upper limb (UPDRS III items 23, 24, 25) in the different experimental conditions. The scores are relative to the current intensity that determined the reaching of the RCE on wrist rigidity.

<table>
<thead>
<tr>
<th>Pulse width (µs)</th>
<th>Rate (Hz)</th>
<th>90</th>
<th>130</th>
<th>170</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>2.6 (2.0)*</td>
<td>2.7 (2.0)*</td>
<td>2.6 (1.9)*</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>2.6 (2.2)*</td>
<td>2.5 (2.1)*</td>
<td>2.5 (2.1)*</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>2.7 (2.3)*</td>
<td>2.6 (2.0)*</td>
<td>2.6 (2.0)*</td>
<td></td>
</tr>
<tr>
<td>450</td>
<td>2.5 (2.0)*</td>
<td>2.6 (2.0)*</td>
<td>2.5 (2.1)*</td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05 v baseline. RCE=Required clinical effect.

**Table 5** Mean (SD) values of intensity (mA) corresponding to the side effect threshold.

<table>
<thead>
<tr>
<th>Pulse width (µs)</th>
<th>Rate (Hz)</th>
<th>90</th>
<th>130</th>
<th>170</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>3.4 (0.5)</td>
<td>2.9 (0.6)</td>
<td>2.6 (0.7)</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>2.4 (0.6)</td>
<td>2.1 (0.5)</td>
<td>1.9 (0.4)</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>1.9 (0.4)</td>
<td>1.7 (0.4)</td>
<td>1.5 (0.3)</td>
<td></td>
</tr>
<tr>
<td>450</td>
<td>1.5 (0.4)</td>
<td>1.4 (0.3)</td>
<td>1.3 (0.3)</td>
<td></td>
</tr>
</tbody>
</table>

The side effects found at a 10 Hz or 50 Hz stimulus rate were qualitatively different from the side effects obtained at 90 Hz, 130 Hz, or 170 Hz. At 10 Hz and 50 Hz the most frequent side effects, restricted to the side contralateral to the stimulated one, were the appearance of or the worsening of tremor and the onset of myoclonic jerks. With a stimulus rate of 90 Hz, 130 Hz, or 170 Hz the side effects noticed were paraesthesias, muscle contractions, and dyskinesias contralateral to the stimulated side.

Figure 1 b shows the IPWCs relative to the side effect threshold. The rate increase from 90 Hz to 170 Hz did not change the type of curve, but a progressive reduction of the side effect threshold value was evident. The differences between the side effect intensity threshold at the different stimulus rate never reached significance within the same pulse width value. On the contrary, the changes of the pulse width values were responsible for greater differences between the side effect threshold values; for every rate value, the increase in the pulse width from 60 to 210 µs, from 60 to 450 µs, and from 120 to 450 µs led always to a significant reduction of the side effect intensity threshold.

**THERAPEUTIC WINDOWS**

We defined the therapeutic window as the difference between the intensity threshold of the stimulus for onset of the side effects and the intensity value necessary to obtain the RCE in the same experimental condition.
Figure 2. Therapeutic windows (difference between the intensity threshold of the stimulus for the onset of side effects and the intensity value necessary to obtain the required clinical effect (RCE) in the different experimental conditions.

Figure 2 shows, for every pulse width value, the difference between the IPWC relative to the clinical effect and the IPWC of the threshold for side effects. This difference, which represents the therapeutic window, is clinically relevant because it is the expression of the range of electrical parameters useful for clinical STN stimulation.

Figure 2 shows the therapeutic windows relative to the different pulse width and rate values. The increase of the pulse width from 60 µs to the higher values (120, 210, 450 µs) showed a progressive reduction of the therapeutic window at every rate value (90, 130, 170 Hz); these reductions were significant at 90 Hz increasing the pulse width value from 60 to 450 µs and at 130 Hz and 170 Hz increasing the pulse width from 60 to 210 µs, and from 60 to 450 µs. For each pulse width value the largest therapeutic window was obtained using a 90 Hz stimulus rate, the increase of the rate to 130 and 170 Hz leading to a narrowing of the therapeutic window (non-significant).

Discussion
In the planning of this study we wanted to eliminate the variables unrelated to the stimulation parameters, which can interfere with the clinical evaluation. To avoid the microlesive effect of the surgical procedure (microhaemorrhage, oedema) we examined the patients at least 3 months after surgery; this time lag was considered sufficient to eliminate any clinical improvement due to the microlesive effect and to obtain a satisfactory stabilisation of the clinical picture.1 To eliminate the possible overlapping of the effect of the omolateral STN stimulation the pulse generator of the examined side was deactivated during the whole test. We solved the problem related to the persistence of a clinical effect after the interruption of the STN stimulation (after effect) by waiting, after every condition, until the baseline wrist rigidity occurred.

As a parameter of the clinical effectiveness of STN stimulation we used the subjective evaluation of contralateral wrist rigidity. This study was finalised to obtain IPWCs at different values of stimulus rate; therefore it was necessary to choose a constant clinical effect clearly detectable in every stimulation condition, strictly correlated with STN stimulation, and arising with a short latency. The disappearance of contralateral wrist rigidity in rest conditions fitted these experimental constraints well and, moreover, it strictly correlated with the effect of deep brain stimulation of the STN on all the motor symptoms of Parkinson’s disease.2 15 Tremor was not suitable for producing IPWCs because it was often fluctuating, apart from the effect of the stimulation, and because many of our patients showed a severe hypertonic-hypokinetic syndrome without tremor. The effect of STN stimulation on akinesia appears, instead, with a longer latency in respect to rigidity, making its evaluation less suitable for drawing the IPWCs.

The four different pulse width values (60, 120, 210, and 450 µs) were conditional on the range possibility offered by the pulse generator (60 to 450 µs), and they were chosen wide apart from each other to better highlight their differences in clinical effectiveness. Five stimulus rate values (10, 50, 90, 130, 170 Hz) were chosen to investigate the whole range of rates that can be produced by the generators, with the purpose of drawing different families of IPWCs with respect to the stimulus rate.

Previous investigations of deep brain stimulation of the STN showed, on the basis of the characteristics of the electrical stimuli,16 17 20 that side effects are probably connected to the spread of the stimulus to the fibre systems near the STN (lemniscus medialis; corticospinal tract) and due to their activation.21 22

We found that the hyperbolic trends of the IPWCs for clinical effectiveness and for the onset of side effects were very similar, suggesting a common mechanism of action. This finding supports the hypothesis that the activation of inhibitory fibres afferent to the STN plays an important part in the clinical effectiveness of stimulation of the STN, as proposed by other authors for the effect of deep brain stimulation of the STN on tremor and for deep brain stimulation of the Gpi.21 23

The trend of the IPWCs obtained at 90, 130, and 170 Hz was similar to the trend of the strength-duration curve of a single electrically stimulated neuronal element.19 By analysing this strength-duration curve it is possible to identify the reobase (intensity value of the stimulus under which it is not possible to obtain any neuronal effect, whatever the pulse width value used) and the chronaxie (stimulus pulse width needed to obtain a response using a stimulus intensity value equal to the double of the reobase value).24 The characteristics of the IPWCs for the clinical and side effects of deep brain stimulation of the STN, showing a striking progressive flattening of the curve at the widest pulse width values (210 µs and 450 µs), are closer to the strength-duration curve typical of the stimulation of a fibre rather than of a neuronal soma; in fact, fibres present a shorter value of chronaxie (50–300 µs) than cell bodies (1000–3000 µs).24 26 These data further underline the role of fibre activation as a possible
mechanism of action for deep brain stimulation of the STN.

From a clinical point of view, our findings provide some information for the setting of the electrical parameters for deep brain stimulation of the STN of patients with Parkinson’s disease. The increase in the pulse width led to an increase in clinical effectiveness, but considerable modifications (from 60 µs to 210 µs or 450 µs; from 120 µs to 450 µs) were necessary to obtain significant differences, with a consequent narrowing of the therapeutic windows.

Rate values of 10 Hz and 50 Hz, even though showing in some cases a limited clinical effect, did not allow us to obtain the RCE; moreover, at these rates the increase in the intensity of the stimulus was often responsible for the onset of tremor or myoclonic jerks, with an amplitude related to the stimulus intensity.

A 90 Hz rate probably represents the threshold for the clinical effectiveness: the RCE was in fact obtained in some patients only with the narrower pulse width values. In some cases increasing the stimulus intensity made it possible to see the onset of side effects similar to those typical of lower rate values (10 Hz and 50 Hz), as tremor or myoclonic jerks.

The stimulation at 130 or 170 Hz was effective in all the patients for every pulse width value. The clinical effectiveness was similar at 130 and 170 Hz was comparable with the therapeutic windows. The side effects found when increasing the stimulus intensity at 130 and 170 Hz were paraesthesias, muscle contractions, and dyskinesias, and they were different from those at 10 and 50 Hz, probably reflecting a different mechanism of action of the electrical stimulation at different rate values.

It seems therefore for deep brain stimulation of the STN that a stimulus rate higher than 90 Hz gives the best clinical effects, whereas, above this value, there are no significant advantages in increasing the stimulus rate up to 170 Hz. Moreover, the slight improvement in clinical effectiveness obtainable using pulse width values larger than 60 µs is accompanied by a significant narrowing of the therapeutic window; therefore, pulse width values larger than 60 µs are probably useful only in selected patients, when the clinical effect is not satisfactory with narrower values. Finally, the finding of a significant improvement of tremor and akinnesia in all the different experimental conditions when the RCE on rigidity was reached could suggest a similar effectiveness of deep brain stimulation of the STN on cardinal Parkinson’s disease symptoms with similar therapeutic windows.1–3

Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: effects of variation in stimulation parameters

M Rizzone, M Lanotte, B Bergamasco, A Tavella, E Torre, G Faccani, A Melcarne and L Lopiano

*J Neurol Neurosurg Psychiatry* 2001 71: 215-219
doi: 10.1136/jnnp.71.2.215

Updated information and services can be found at:
http://jnnp.bmj.com/content/71/2/215

**References**

This article cites 22 articles, 6 of which you can access for free at:
http://jnnp.bmj.com/content/71/2/215#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: CNS (not psychiatric) (1945)
- Parkinson's disease (690)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/